Intermittent hypoxia alleviates increased VEGF and pro‑angiogenic potential in liver cancer cells

Dong,Gang; Lin,Xia‑Hui; Liu,Hua‑Hua; Gao,Dong‑Mei; Cui,Jie‑Feng; Ren,Zheng‑Gang; Chen,Rong‑Xin

doi:10.3892/ol.2019.10486

Intermittent hypoxia alleviates increased VEGF and pro‑angiogenic potential in liver cancer cells

Authors:
- Gang Dong
- Xia‑Hui Lin
- Hua‑Hua Liu
- Dong‑Mei Gao
- Jie‑Feng Cui
- Zheng‑Gang Ren
- Rong‑Xin Chen
View Affiliations

Affiliations: Liver Cancer Institute, Zhongshan Hospital, Fudan University and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, P.R. China
Published online on: June 18, 2019 https://doi.org/10.3892/ol.2019.10486
Pages: 1831-1839
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor (VEGF) is an important angiogenic factor. The VEGF rebound induced by hypoxia following transarterial embolization/chemoembolization for primary liver cancer is associated with treatment failure and poor survival rates in patients. The present study investigated the ability of intermittent hypoxia to alleviate the acute hypoxia‑induced increase of VEGF and decrease the pro‑angiogenic potential of liver cancer cells. The liver cancer cells were exposed to normoxia, or acute or intermittent hypoxia, and the expression of VEGF was determined using reverse transcription‑quantitative polymerase chain reaction analysis and western blotting. The pro‑angiogenic effects of acute or intermittent hypoxia‑exposed liver cancer cells on endothelial cells were assessed in vitro and in vivo. The expression of VEGF in the liver cancer cells exposed to intermittent hypoxia was significantly lower than that in cells exposed to acute hypoxia. Compared with conditioned medium (CM) from acute hypoxia‑exposed liver cancer cells, the CM from intermittent hypoxia‑exposed liver cancer cells showed markedly less promotion of proliferation and tube formation in endothelial cells. Activation of the reactive oxygen species (ROS)/NF‑κB/hypoxia‑inducible factor‑1α/VEGF signaling pathway was increased in the liver cancer cells exposed to acute hypoxia. Exposure to ROS scavenger N‑acetyl‑cysteine or NF‑κB inhibitor PDTC inhibited the activation of the above pathway and the expression of VEGF induced by acute hypoxia. The in vivo pro‑angiogenic effects of intermittent hypoxia‑exposed liver cancer cells on endothelial cells were significantly reduced compared with those of acute hypoxia‑exposed liver cancer cells. Intermittent hypoxia may alleviate the acute hypoxia‑induced increase of VEGF and decrease the pro‑angiogenic potential of liver cancer cells, suggesting a novel treatment strategy.

View Figures

View References

1	Chua CW and Choo SP: Targeted therapy in hepatocellular carcinoma. Int J Hepatol. 2011:1–11. 2011. View Article : Google Scholar
2	Zhang ZM, Guo JX, Zhang ZC, Jiang N, Zhang ZY and Pan LJ: Therapeutic options for intermediate-advanced hepatocellular carcinoma. World J Gastroenterol. 17:1685–1689. 2011. View Article : Google Scholar : PubMed/NCBI
3	Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, Lee PC, Chang FY and Lee SD: Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther. 23:129–135. 2006. View Article : Google Scholar : PubMed/NCBI
4	Guan YS, He Q and Wang MQ: Transcatheter arterial chemoembolization: History for more than 30 years. ISRN Gastroenterol. 2012:4806502012. View Article : Google Scholar : PubMed/NCBI
5	Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E, Manousou P and Burroughs AK: TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 8:1623–1641. 2008. View Article : Google Scholar : PubMed/NCBI
6	Zhang Y and Lai Y: A combination of anti-angiogenesis with endostatin and transcatheter arterial chemoembolization (TACE) enhances antitumour effects in a rabbit VX2 liver tumor. Radiol Soc North Am 2010 Sci Assembly Meeting. 2010.
7	Hanks BA, Suhocki PV, DeLong DM, Doan PL, Liu E, Tsai AL, Burke CT, Bernard SA, O'Neil BH and Morse MA: The efficacy and tolerability of transarterial chemo-embolization (TACE) compared with transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 26:45952008. View Article : Google Scholar : PubMed/NCBI
8	Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A and Farinati F: Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness. Am J Gastroenterol. 103:914–921. 2008. View Article : Google Scholar : PubMed/NCBI
9	Chao Y, Wu CY, Kuo CY, Wang JP, Luo JC, Kao CH, Lee RC, Lee WP and Li CP: Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization. Hepatol Int. 7:883–892. 2013. View Article : Google Scholar : PubMed/NCBI
10	Jia ZZ, Jiang GM and Feng YL: Serum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer. Chin Med Sci J. 26:158–162. 2010. View Article : Google Scholar
11	Liu K, Min XL, Peng J, Yang K, Yang L and Zhang XM: The changes of HIF-1α and VEGF expression after TACE in patients with hepatocellular carcinoma. J Clin Med Res. 8:297–302. 2016. View Article : Google Scholar : PubMed/NCBI
12	Jia ZZ, Jiang GM and Feng YL: Serum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer. Chin Med Sci J. 26:158–162. 2011. View Article : Google Scholar : PubMed/NCBI
13	Britten CD, Gomes AS, Wainberg ZA, Elashoff D, Amado R, Xin Y, Busuttil RW, Slamon DJ and Finn RS: Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study. BMC Cancer. 12:162012. View Article : Google Scholar : PubMed/NCBI
14	Pinter M, Ulbrich G, Sieghart W, Kölblinger C, Reiberger T, Li S, Ferlitsch A, Müller C, Lammer J and Peck-Radosavljevic M: Hepatocellular carcinoma: A phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo. Radiology. 277:903–912. 2015. View Article : Google Scholar : PubMed/NCBI
15	Jin B, Wang D, Lewandowski RJ, Riaz A, Ryu RK, Sato KT, Larson AC, Salem R and Omary RA: Chemoembolization endpoints: Effect on survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol. 196:919–928. 2011. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Lu D, Liao Y, Zhu SH, Chen QC, Xie DM, Liao JJ, Feng X, Jiang MH and He W: Bone-derived Nestin-positive mesenchymal stem cells improve cardiac function via recruiting cardiac endothelial cells after myocardial infarction. Stem Cell Res Ther. 10:1272019. View Article : Google Scholar : PubMed/NCBI
18	Liu M, Ning X, Li R, Yang Z, Yang X, Sun S and Qian Q: Signalling pathways involved in hypoxia-induced renal fibrosis. J Cell Mol Med. 21:1248–1259. 2017. View Article : Google Scholar : PubMed/NCBI
19	Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG and Karin M: NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 453:807–811. 2008. View Article : Google Scholar : PubMed/NCBI
20	Huang Q, Zhan L, Cao H, Li J, Lyu Y, Guo X, Zhang J, Ji L, Ren T, An J, et al: Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways. Autophagy. 12:999–1014. 2016. View Article : Google Scholar : PubMed/NCBI
21	Bonello S, Zähringer C, BelAiba RS, Djordjevic T, Hess J, Michiels C, Kietzmann T and Görlach A: Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol. 27:755–761. 2007. View Article : Google Scholar : PubMed/NCBI
22	Diebold I, Djordjevic T, Hess J and Görlach A: Rac-1 promotes pulmonary artery smooth muscle cell proliferation by upregulation of plasminogen activator inhibitor-1: Role of NFkappaB-dependent hypoxia-inducible factor-1alpha transcription. Thromb Haemost. 100:1021–1028. 2008. View Article : Google Scholar : PubMed/NCBI
23	El-Halawany MS, Ismail HM, Zeeneldin AA, Elfiky A, Tantawy M, Kobaisi MH, Hamed I and Abdel Wahab AH: Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment. Biomed Res Int. 2015:6497502015. View Article : Google Scholar : PubMed/NCBI
24	Petrillo M, Patella F, Pesapane F, Suter MB, Ierardi AM, Angileri SA, Floridi C, de Filippo M and Carrafiello G: Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments. Future Oncol. 14:2957–2967. 2018. View Article : Google Scholar : PubMed/NCBI
25	Ahluwalia A, Jones MK, Matysiak-Budnik T and Tarnawski AS: VEGF and colon cancer growth beyond angiogenesis: Does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism? Curr Pharm Des. 20:1041–1044. 2014. View Article : Google Scholar : PubMed/NCBI
26	Petersen W, Pufe T, Stärke C, Fuchs T, Kopf S, Neumann W, Zantop T, Paletta J, Raschke M and Becker R: The effect of locally applied vascular endothelial growth factor on meniscus healing: Gross and histological findings. Arch Orthop Trauma Surg. 127:235–240. 2007. View Article : Google Scholar : PubMed/NCBI
27	Olszewska-Pazdrak B, Hein TW, Olszewska P and Carney DH: Chronic hypoxia attenuates VEGF signaling and angiogenic responses by downregulation of KDR in human endothelial cells. Am J Physiol Cell Physiol. 296:C1162–C1170. 2009. View Article : Google Scholar : PubMed/NCBI
28	Lee G, Won HS, Lee YM, Choi JW, Oh TI, Jang JH, Choi DK, Lim BO, Kim YJ, Park JW, et al: Oxidative dimerization of PHD2 is responsible for its inactivation and contributes to metabolic reprogramming via HIF-1α activation. Sci Rep. 6:189282016. View Article : Google Scholar : PubMed/NCBI
29	Chen A, Sceneay J, Gödde N, Kinwel T, Ham S, Thompson EW, Humbert PO and Möller A: Intermittent hypoxia induces a metastatic phenotype in breast cancer. Oncogene. 37:4214–4225. 2018. View Article : Google Scholar : PubMed/NCBI
30	Louie E, Nik S, Chen JS, Schmidt M, Song B, Pacson C, Chen XF, Park S, Ju J and Chen EI: Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res. 12:R942010. View Article : Google Scholar : PubMed/NCBI